GeneaMed

GeneaMed is a fusion of ideas, creativity and years of experience in the treatment and diagnosis of blood proliferative disorders. The company develops innovative therapeutics for severe neoplastic diseases. The latest invention of GeneaMed is the use of dendrimer-based nanoparticles in the targeted treatment of a group of chronic B-cells Lymphoproliferative Disorders (B-CLPDs) with the most common Chronic Lymphocytic Leukemia (CLL). Our invention won the Golden Medal at the International Invention Fairs "Concours Lepine 2013" in Paris. This year we have won "Master of Innovation 2017" Award at Central European Forum of Biotechnology and Innovative Bioeconomy in Lodz. GeneaMed has three international patent applications. We have obtained positive results on cells from patients and on customer cell lines in vivo. Promising results were also obtained after in vivo trials on animals.